Shanghai Junshi Biosciences Co., Ltd. (1877.HK)
HKD 16.26
(-0.49%)
HKD 16.26
(-0.49%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 4.02 Billion CNY | 44.58% |
| 2022 | 2.78 Billion CNY | 2.34% |
| 2021 | 2.71 Billion CNY | 25.3% |
| 2020 | 2.16 Billion CNY | 51.31% |
| 2019 | 1.43 Billion CNY | 53.17% |
| 2018 | 936.17 Million CNY | 832.68% |
| 2017 | 100.37 Million CNY | 347.8% |
| 2016 | 22.41 Million CNY | 58.27% |
| 2015 | 14.16 Million CNY | 8.34% |
| 2014 | 13.07 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 5 Billion CNY | 24.45% |
| 2024 Q2 | 4.38 Billion CNY | -12.41% |
| 2023 Q3 | 3.24 Billion CNY | 8.53% |
| 2023 Q4 | 4.02 Billion CNY | 23.78% |
| 2023 FY | 4.02 Billion CNY | 44.58% |
| 2023 Q1 | 2.85 Billion CNY | 2.68% |
| 2023 Q2 | 2.99 Billion CNY | 4.81% |
| 2022 FY | 2.78 Billion CNY | 2.34% |
| 2022 Q4 | 2.78 Billion CNY | 3.94% |
| 2022 Q3 | 2.67 Billion CNY | 13.58% |
| 2022 Q2 | 2.35 Billion CNY | -11.12% |
| 2022 Q1 | 2.65 Billion CNY | -2.46% |
| 2021 Q3 | 1.89 Billion CNY | -4.28% |
| 2021 Q4 | 2.71 Billion CNY | 43.21% |
| 2021 Q1 | 2.29 Billion CNY | 5.73% |
| 2021 FY | 2.71 Billion CNY | 25.3% |
| 2021 Q2 | 1.98 Billion CNY | -13.55% |
| 2020 Q1 | - CNY | -100.0% |
| 2020 FY | 2.16 Billion CNY | 51.31% |
| 2020 Q2 | 2.16 Billion CNY | 0.0% |
| 2020 Q3 | 1.77 Billion CNY | -17.98% |
| 2020 Q4 | 2.16 Billion CNY | 22.06% |
| 2019 Q1 | 1.12 Billion CNY | 19.82% |
| 2019 FY | 1.43 Billion CNY | 53.17% |
| 2019 Q4 | 1.43 Billion CNY | 0.0% |
| 2019 Q2 | 1.2 Billion CNY | 7.84% |
| 2018 Q3 | 471.98 Million CNY | 22.83% |
| 2018 FY | 936.17 Million CNY | 832.68% |
| 2018 Q4 | 936.17 Million CNY | 98.35% |
| 2018 Q2 | 384.26 Million CNY | 0.0% |
| 2018 Q1 | - CNY | -100.0% |
| 2017 FY | 100.37 Million CNY | 347.8% |
| 2017 Q1 | 19.03 Million CNY | 0.4% |
| 2017 Q2 | 19.03 Million CNY | 0.0% |
| 2017 Q4 | 100.37 Million CNY | 0.0% |
| 2016 FY | 22.41 Million CNY | 58.27% |
| 2016 Q1 | 4.64 Million CNY | -67.21% |
| 2016 Q2 | 4.64 Million CNY | 0.0% |
| 2016 Q3 | 18.96 Million CNY | 308.35% |
| 2016 Q4 | 18.96 Million CNY | 0.0% |
| 2015 Q2 | 20.72 Million CNY | 0.0% |
| 2015 Q1 | 20.72 Million CNY | 58.58% |
| 2015 Q4 | 14.16 Million CNY | 0.0% |
| 2015 Q3 | 14.16 Million CNY | -31.68% |
| 2015 FY | 14.16 Million CNY | 8.34% |
| 2014 FY | 13.07 Million CNY | 0.0% |
| 2014 Q4 | 13.07 Million CNY | 0.0% |
| 2014 Q3 | 13.07 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 152.81 Million HKD | -2532.056% |
| CK Life Sciences Int'l., (Holdings) Inc. | 7.05 Billion HKD | 43.013% |